Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-20-7400-3347
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable
Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions
What is Urovant Sciences' stock symbol?
Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV."
How were Urovant Sciences' earnings last quarter?
Urovant Sciences Ltd (NASDAQ:UROV) posted its earnings results on Tuesday, November, 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.15) by $0.30. View Urovant Sciences' Earnings History.
When is Urovant Sciences' next earnings date?
What price target have analysts set for UROV?
3 analysts have issued 1-year price targets for Urovant Sciences' shares. Their forecasts range from $24.00 to $28.00. On average, they anticipate Urovant Sciences' share price to reach $25.33 in the next twelve months. This suggests a possible upside of 105.5% from the stock's current price. View Analyst Price Targets for Urovant Sciences.
What is the consensus analysts' recommendation for Urovant Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urovant Sciences.
What are Wall Street analysts saying about Urovant Sciences stock?
Here are some recent quotes from research analysts about Urovant Sciences stock:
- 1. According to Zacks Investment Research, "Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. " (11/6/2019)
- 2. HC Wainwright analysts commented, "Valuation and financial considerations appear noteworthy. From our vantage point, DSP’s involvement could meaningfully reduce any future need for Urovant to access equity or debt markets for further capital to fund the launch of vibegron." (9/9/2019)
Has Urovant Sciences been receiving favorable news coverage?
Media stories about UROV stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urovant Sciences earned a news impact score of -1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Urovant Sciences.
Are investors shorting Urovant Sciences?
Urovant Sciences saw a increase in short interest in November. As of November 15th, there was short interest totalling 916,700 shares, an increase of 18.7% from the October 31st total of 772,000 shares. Based on an average daily volume of 58,800 shares, the days-to-cover ratio is presently 15.6 days. Approximately 12.6% of the company's stock are short sold. View Urovant Sciences' Current Options Chain.
Who are some of Urovant Sciences' key competitors?
Some companies that are related to Urovant Sciences include Constellation Pharmaceuticals (CNST), Aurinia Pharmaceuticals (AUPH), Nabriva Therapeutics (NBRV), Athenex (ATNX), Esperion Therapeutics (ESPR), Innoviva (INVA), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN), Enanta Pharmaceuticals (ENTA), Principia Biopharma (PRNB), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN), ArQule (ARQL) and NextCure (NXTC).
What other stocks do shareholders of Urovant Sciences own?
Who are Urovant Sciences' key executives?
Urovant Sciences' management team includes the folowing people:
- Mr. Keith A. Katkin, CEO & Director (Age 48)
- Ms. Christine G. Ocampo, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 47)
- Mr. Michael E. McFadden, Chief Commercial Officer of USI (Age 52)
- Dr. David Hovland, Sr. VP of Global Regulatory Affairs
- Ms. Nori Ebersole, Sr. VP & Chief HR Officer of USI (Age 56)
When did Urovant Sciences IPO?
(UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.
Who are Urovant Sciences' major shareholders?
Urovant Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wildcat Capital Management LLC (0.72%), Point72 Asset Management L.P. (0.16%), Millennium Management LLC (0.13%), LVW Advisors LLC (0.13%) and First Trust Advisors LP (0.06%). Company insiders that own Urovant Sciences stock include Andrew Lo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc and Sciences Ltd Roivant. View Institutional Ownership Trends for Urovant Sciences.
Which major investors are selling Urovant Sciences stock?
Which major investors are buying Urovant Sciences stock?
UROV stock was acquired by a variety of institutional investors in the last quarter, including Wildcat Capital Management LLC, Point72 Asset Management L.P., LVW Advisors LLC and First Trust Advisors LP. Company insiders that have bought Urovant Sciences stock in the last two years include Andrew Lo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc and Sciences Ltd Roivant. View Insider Buying and Selling for Urovant Sciences.
How do I buy shares of Urovant Sciences?
Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Urovant Sciences' stock price today?
One share of UROV stock can currently be purchased for approximately $12.33.
How big of a company is Urovant Sciences?
Urovant Sciences has a market capitalization of $374.59 million. The company earns $-111,350,000.00 in net income (profit) each year or ($4.43) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe.View Additional Information About Urovant Sciences.
What is Urovant Sciences' official website?
How can I contact Urovant Sciences?
Urovant Sciences' mailing address is 11-12 ST. JAMES S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]
MarketBeat Community Rating for Urovant Sciences (NASDAQ UROV)
MarketBeat's community ratings are surveys of what our community members think about Urovant Sciences and other stocks. Vote "Outperform" if you believe UROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
